A New Possibility for Advanced Prostate Cancer
Antibody‑drug conjugates targeting HER2 may open a new treatment path for advanced prostate cancer
The article describes a case series where the HER2‑targeting antibody‑drug conjugate trastuzumab deruxtecan achieved significant tumor shrinkage in two advanced prostate cancer patients, suggesting that HER2 expression may be a viable target beyond breast cancer.
HER2‑targeting therapy provides a potential new option for advanced prostate cancer patients who have exhausted standard treatments, expanding the therapeutic arsenal for this disease.
Evidence level: Állatkísérletes. Állatmodellben vizsgálták.
Related signals
- Apalutamide Treatment and Metastasis‑free Survival in Prostate Cancer
- The prostate cancer conundrum revisited: Treatment changes and prostate cancer mortality declines
- The contemporary management of prostate cancer
- Extracellular TROP2 Fragment Identified as a Potential Biomarker and Metastasis Driver
- Overall survival of prostate cancer patients treated with Lu‑177 PSMA 617 (Pluvicto®) in a multidisciplinary setting— a single center experience